glp-1 sleep apnea trial glp 1 GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction 📊 New late-stage clinical trial

Butsch WS et al. 2025 (Clinical Obesity / Obesity Pillars) Retrospective analysis of 461,382 GLP-1 users. 12.7% had new nutritional deficiency by 6 months, 22.4% by 12 months. Muscle loss diagnoses also increased over time

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed diabetes and weight management, but emerging evidence links these medications to increased gallbladder complications

Tirzepatide independently causes a modest heart rate increase, averaging 2-4 beats per minute in the SURMOUNT clinical trials

Promoting lean muscle growth , which aids in fat loss